Entera Bio Ltd
ILILSEntera Bio Ltd (US:ENTX) — Biotechnology: Biological Products (No Diagnostic Substances). Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 1. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.
Over het Bedrijf
- Website
- enterabio.com
- Beleggersrelaties
- investors.enterabio.com/
- Sector
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Hoofdkantoor
- JERUSALEM, Israel
- Management
- Miranda J. Toledano
- Recente Rapporten
- Werknemers
- 20
- Uitstaande Aandelen
- 173.14 mln. per 2026-08-03
- Free Float
- 126.58 mln.
- Marktkapitalisatie
- 507.6 mln. USD
- Insiders
- 5.43%
- Institutionele Beleggers
- 34.09%
- Branche (SIC)
- Biological Products, (No Diagnostic Substances)
- P/E
- verlies
- P/B
- 21.2
- FCF
- −11.0 mln. USD
- Schuld
- 3.89 mln. USDnegatieve FCF — geen dekking
- Winst en FCF — voor de 12 maanden tot 30.06.2026 (het laatste rapport van het bedrijf).
- Nettowinst
- NAV
Beschrijving
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Beurzen en Tickers
| Beurs | Ticker | Valuta | Prijs | Type |
|---|---|---|---|---|
| US USA Stocks | ENTX | USD | 3.12 +0.65% | gewone aandelen |
Nieuws Deze Week
Persberichten van de investeerderswebsite van het bedrijf, dagelijks bijgewerkt. Links leiden naar de website van het bedrijf. De koppen zijn in de oorspronkelijke taal, zoals op de bedrijfswebsite.
Grootste Aandeelhouders
| Houder | Belang | Aandelen | Rapportdatum |
|---|---|---|---|
| Knoll Capital Management… | 3.38% | 5.88 mln. | 2026-06-30 |
| BVF Inc. | 1.39% | 2.43 mln. | 2026-06-30 |
| TOLEDANO MIRANDA JAYNE (… | ≈0.49% | 847 135 | 2026-07-14 |
| Siren, L.L.C. | 0.42% | 736 457 | 2026-06-30 |
| Renaissance Technologies… | 0.21% | 368 847 | 2026-06-30 |
| LIEBERMAN GERALD M (Dire… | ≈0.21% | 363 254 | 2025-12-31 |
| Parkman Healthcare Partn… | 0.16% | 274 497 | 2026-06-30 |
| PNC Financial Services G… | 0.16% | 273 031 | 2026-06-30 |
| ELLIS SEAN (Director) | ≈0.12% | 208 132 | 2026-08-07 |
| Seven Fleet Capital Mana… | 0.11% | 191 354 | 2026-06-30 |
| BURSHTEIN GREGORY (Offic… | ≈0.11% | 189 033 | 2026-05-07 |
| Fidelity Concord Street… | 0.1% | 178 259 | 2026-08-31 |
| GALITZER HILLEL M.D. (Ch… | ≈0.09% | 163 566 | 2026-05-07 |
| TAITEL HAYA (Director) | ≈0.07% | 119 269 | 2026-08-07 |
| MALCA YONATAN (Director) | ≈0.06% | 100 231 | 2026-08-07 |
| OSTROV GERALD M (Directo… | ≈0.04% | 75 657 | 2025-12-31 |
| HighTower Advisors, LLC | 0.04% | 74 573 | 2026-06-30 |
| HRT Financial LP | 0.04% | 72 486 | 2026-06-30 |
| Schonfeld Strategic Advi… | 0.03% | 58 871 | 2026-06-30 |
| GERMANO GENO J (Director… | ≈0.02% | 40 000 | 2026-03-09 |
| YAACOV-GARBELI DANA CPA… | — | — | 2026-05-07 |
Log in met Google